Understanding "Hybrid Immunity" : Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity.
METHODS: We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.
RESULTS: Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01).
CONCLUSIONS: Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e439-e449 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Epsi, Nusrat J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2023 Date Revised 20.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac392 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341309710 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341309710 | ||
| 003 | DE-627 | ||
| 005 | 20231226011459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac392 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341309710 | ||
| 035 | |a (NLM)35608504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Epsi, Nusrat J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Understanding "Hybrid Immunity" |b Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2023 | ||
| 500 | |a Date Revised 20.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity | ||
| 520 | |a METHODS: We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups | ||
| 520 | |a RESULTS: Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01) | ||
| 520 | |a CONCLUSIONS: Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody response | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a vaccine breakthrough | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a Ad26COVS1 |2 NLM | |
| 650 | 7 | |a JT2NS6183B |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Richard, Stephanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Lindholm, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Mende, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesan, Anuradha |e verfasserin |4 aut | |
| 700 | 1 | |a Huprikar, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Lalani, Tahaniyat |e verfasserin |4 aut | |
| 700 | 1 | |a Fries, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a Maves, Ryan C |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Rhonda E |e verfasserin |4 aut | |
| 700 | 1 | |a Larson, Derek T |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alfred |e verfasserin |4 aut | |
| 700 | 1 | |a Chi, Sharon W |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, Carlos J |e verfasserin |4 aut | |
| 700 | 1 | |a Ewers, Evan C |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Milissa U |e verfasserin |4 aut | |
| 700 | 1 | |a Berjohn, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Libraty, Daniel H |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Margaret Sanchez |e verfasserin |4 aut | |
| 700 | 1 | |a English, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Rozman, Julia S |e verfasserin |4 aut | |
| 700 | 1 | |a Mody, Rupal M |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Samuels, Emily C |e verfasserin |4 aut | |
| 700 | 1 | |a Nwachukwu, Princess |e verfasserin |4 aut | |
| 700 | 1 | |a Tso, Marana S |e verfasserin |4 aut | |
| 700 | 1 | |a Scher, Ann I |e verfasserin |4 aut | |
| 700 | 1 | |a Byrne, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Rusiecki, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Simons, Mark P |e verfasserin |4 aut | |
| 700 | 1 | |a Tribble, David |e verfasserin |4 aut | |
| 700 | 1 | |a Broder, Christopher C |e verfasserin |4 aut | |
| 700 | 1 | |a Agan, Brian K |e verfasserin |4 aut | |
| 700 | 1 | |a Burgess, Timothy H |e verfasserin |4 aut | |
| 700 | 1 | |a Laing, Eric D |e verfasserin |4 aut | |
| 700 | 1 | |a Pollett, Simon D |e verfasserin |4 aut | |
| 700 | 0 | |a Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential COVID-19 Cohort Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Cowden, J |e investigator |4 oth | |
| 700 | 1 | |a Darling, M |e investigator |4 oth | |
| 700 | 1 | |a DeLeon, S |e investigator |4 oth | |
| 700 | 1 | |a Lindholm, D |e investigator |4 oth | |
| 700 | 1 | |a Markelz, A |e investigator |4 oth | |
| 700 | 1 | |a Mende, K |e investigator |4 oth | |
| 700 | 1 | |a Merritt, S |e investigator |4 oth | |
| 700 | 1 | |a Merritt, T |e investigator |4 oth | |
| 700 | 1 | |a Turner, N |e investigator |4 oth | |
| 700 | 1 | |a Wellington, T |e investigator |4 oth | |
| 700 | 1 | |a Bazan, S |e investigator |4 oth | |
| 700 | 1 | |a Love, P K |e investigator |4 oth | |
| 700 | 1 | |a Dimascio-Johnson, N |e investigator |4 oth | |
| 700 | 1 | |a Ewers, E |e investigator |4 oth | |
| 700 | 1 | |a Gallagher, K |e investigator |4 oth | |
| 700 | 1 | |a Larson, D |e investigator |4 oth | |
| 700 | 1 | |a Rutt, A |e investigator |4 oth | |
| 700 | 1 | |a Blair, P |e investigator |4 oth | |
| 700 | 1 | |a Chenoweth, J |e investigator |4 oth | |
| 700 | 1 | |a Clark, D |e investigator |4 oth | |
| 700 | 1 | |a Chambers, S |e investigator |4 oth | |
| 700 | 1 | |a Colombo, C |e investigator |4 oth | |
| 700 | 1 | |a Colombo, R |e investigator |4 oth | |
| 700 | 1 | |a Conlon, C |e investigator |4 oth | |
| 700 | 1 | |a Everson, K |e investigator |4 oth | |
| 700 | 1 | |a Faestel, P |e investigator |4 oth | |
| 700 | 1 | |a Ferguson, T |e investigator |4 oth | |
| 700 | 1 | |a Gordon, L |e investigator |4 oth | |
| 700 | 1 | |a Grogan, S |e investigator |4 oth | |
| 700 | 1 | |a Lis, S |e investigator |4 oth | |
| 700 | 1 | |a Mount, C |e investigator |4 oth | |
| 700 | 1 | |a Musfeldt, D |e investigator |4 oth | |
| 700 | 1 | |a Odineal, D |e investigator |4 oth | |
| 700 | 1 | |a Perreault, M |e investigator |4 oth | |
| 700 | 1 | |a Robb-McGrath, W |e investigator |4 oth | |
| 700 | 1 | |a Sainato, R |e investigator |4 oth | |
| 700 | 1 | |a Schofield, C |e investigator |4 oth | |
| 700 | 1 | |a Skinner, C |e investigator |4 oth | |
| 700 | 1 | |a Stein, M |e investigator |4 oth | |
| 700 | 1 | |a Switzer, M |e investigator |4 oth | |
| 700 | 1 | |a Timlin, M |e investigator |4 oth | |
| 700 | 1 | |a Wood, S |e investigator |4 oth | |
| 700 | 1 | |a Banks, S |e investigator |4 oth | |
| 700 | 1 | |a Carpenter, R |e investigator |4 oth | |
| 700 | 1 | |a Kim, L |e investigator |4 oth | |
| 700 | 1 | |a Kronmann, K |e investigator |4 oth | |
| 700 | 1 | |a Lalani, T |e investigator |4 oth | |
| 700 | 1 | |a Lee, T |e investigator |4 oth | |
| 700 | 1 | |a Smith, A |e investigator |4 oth | |
| 700 | 1 | |a Smith, R |e investigator |4 oth | |
| 700 | 1 | |a Tant, R |e investigator |4 oth | |
| 700 | 1 | |a Warkentien, T |e investigator |4 oth | |
| 700 | 1 | |a Berjohn, C |e investigator |4 oth | |
| 700 | 1 | |a Cammarata, S |e investigator |4 oth | |
| 700 | 1 | |a Kirkland, N |e investigator |4 oth | |
| 700 | 1 | |a Libraty, D |e investigator |4 oth | |
| 700 | 1 | |a Maves, R |e investigator |4 oth | |
| 700 | 1 | |a Utz, G |e investigator |4 oth | |
| 700 | 1 | |a Chi, S |e investigator |4 oth | |
| 700 | 1 | |a Flanagan, R |e investigator |4 oth | |
| 700 | 1 | |a Jones, M |e investigator |4 oth | |
| 700 | 1 | |a Lucas, C |e investigator |4 oth | |
| 700 | 1 | |a Madar, C |e investigator |4 oth | |
| 700 | 1 | |a Miyasato, K |e investigator |4 oth | |
| 700 | 1 | |a Uyehara, C |e investigator |4 oth | |
| 700 | 1 | |a Agan, B |e investigator |4 oth | |
| 700 | 1 | |a Andronescu, L |e investigator |4 oth | |
| 700 | 1 | |a Austin, A |e investigator |4 oth | |
| 700 | 1 | |a Broder, C |e investigator |4 oth | |
| 700 | 1 | |a Burgess, T |e investigator |4 oth | |
| 700 | 1 | |a Byrne, C |e investigator |4 oth | |
| 700 | 1 | |a Chung, K |e investigator |4 oth | |
| 700 | 1 | |a Davies, J |e investigator |4 oth | |
| 700 | 1 | |a English, C |e investigator |4 oth | |
| 700 | 1 | |a Epsi, N |e investigator |4 oth | |
| 700 | 1 | |a Fox, C |e investigator |4 oth | |
| 700 | 1 | |a Fritschlanski, M |e investigator |4 oth | |
| 700 | 1 | |a Grother, M |e investigator |4 oth | |
| 700 | 1 | |a Hadley, A |e investigator |4 oth | |
| 700 | 1 | |a Hickey, P |e investigator |4 oth | |
| 700 | 1 | |a Laing, E |e investigator |4 oth | |
| 700 | 1 | |a Lanteri, C |e investigator |4 oth | |
| 700 | 1 | |a Livezey, J |e investigator |4 oth | |
| 700 | 1 | |a Malloy, A |e investigator |4 oth | |
| 700 | 1 | |a Mohammed, R |e investigator |4 oth | |
| 700 | 1 | |a Morales, C |e investigator |4 oth | |
| 700 | 1 | |a Nwachukwu, P |e investigator |4 oth | |
| 700 | 1 | |a Olsen, C |e investigator |4 oth | |
| 700 | 1 | |a Parmelee, E |e investigator |4 oth | |
| 700 | 1 | |a Pollett, S |e investigator |4 oth | |
| 700 | 1 | |a Richard, S |e investigator |4 oth | |
| 700 | 1 | |a Rozman, J |e investigator |4 oth | |
| 700 | 1 | |a Rusiecki, J |e investigator |4 oth | |
| 700 | 1 | |a Samuels, E |e investigator |4 oth | |
| 700 | 1 | |a Nwachukwu, P |e investigator |4 oth | |
| 700 | 1 | |a Tso, M |e investigator |4 oth | |
| 700 | 1 | |a Sanchez, M |e investigator |4 oth | |
| 700 | 1 | |a Scher, A |e investigator |4 oth | |
| 700 | 1 | |a Simons, M |e investigator |4 oth | |
| 700 | 1 | |a Snow, A |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e439-e449 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e439-e449 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac392 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e439-e449 | ||